New incident report
Incident Report Number: 2020-0589
Registrant Reference Number: 2019-US-031914
Registrant Name (Full Legal Name no abbreviations): Wellmark International
Address: 100 Stone Road West, Suite 111
City: Guelph
Prov / State: Ontario
Country: Canada
Postal Code: N1G5L3
Domestic Animal
Country: UNITED STATES
Prov / State: NEW YORK
PMRA Registration No. PMRA Submission No. EPA Registration No. 2724-803-270
Product Name: Adams Flea and Tick Spray, 16 fl oz
Liquid
Yes
Unknown
Site: Animal / Usage sur un animal domestique
Unknown
Animal's Owner
Dog / Chien
Miniature pinscher
1
Female
8
7
lbs
Skin
>24 hrs <=3 days / >24 h <=3 jours
>8 hrs <=24 hrs / > 8 h < = 24 h
System
Persisted until death
No
No
Died
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
On 19-Nov-2019 a small amount of product was applied to the dog on the back of its neck, tail, and abdomen to treat existing fleas. On 20-Nov-2019 the dog developed lethargy and on 21-Nov-2019 the dog was found dead. No veterinary evaluation occurred, and a necropsy was not performed. No further information was provided.
Death
Assessment: This product has a wide margin of safety and the severity of clinical signs reported in this case, including death, is not expected with labeled product use. The symptoms shown by the dog could have resulted from a variety of other causes including metabolic disease, cancer, trauma, exposure to other insecticides and infection. Veterinary examination and diagnostics including necropsy may have provided additional information about the cause of this dog's death but were not pursued by the animal owner. The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.